Pharming Group

Pharming Group P/TBV

The Price to Tangible Book Value (P/TBV) of Pharming Group (PHARM.AS) as of Nov 19, 2026 is 4.03. In the previous year, Price to Tangible Book Value (P/TBV) was 6.87 — a change of -41.29% (lower).

P/TBV

4.03

YoY

-41.29%

Last updated:

Price to Tangible Book Value (P/TBV) of Pharming Group is 2025 4.03 . Price to Tangible Book Value (P/TBV) of Pharming Group was 2024 6.87 . It decreases by -41.29% lower compared to the previous year.

The Pharming Group P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
73.49 USD
Jan 1, 2019
29.18 USD
Jan 1, 2020
12.32 USD
Jan 1, 2021
10.14 USD
Jan 1, 2022
8.53 USD
Jan 1, 2023
8.71 USD
Jan 1, 2024
6.87 USD
Jan 1, 2025
4.03 USD
The Pharming Group P/TBV history
YEARP/TBVYoY
4.03-41.29%
6.87-21.13%
8.71+2.15%
8.53-15.86%
10.14-17.74%
12.32-57.77%
29.18-60.30%
73.49-349.51%
-29.45-26.46%
-40.05-191.88%
43.59+40.15%
31.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharming Group Stock analysis

What does Pharming Group do? Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharming Group stock

Price to Tangible Book Value (P/TBV) of Pharming Group is 4.03 in 2025.

Price to Tangible Book Value (P/TBV) of Pharming Group changed from 6.87 to 4.03, representing a -41.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Pharming Group since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Pharming Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Pharming Group

All Key Metrics — Pharming Group